Top

Clinical Research in Cardiology

Published in:

Open Access 01-02-2022 | Fifth Disease | Letter to the Editors

Fulminant parvovirus B19 myocarditis after chemotherapy: full recovery after antiviral therapy with tenofovir

Authors: Tobias Koenig, Tibor Kempf, Heinz-Peter Schultheiss, Markus Cornberg, Johann Bauersachs, Andreas Schäfer

Published in: Clinical Research in Cardiology | Issue 2/2022

Excerpt

Sirs: …

Available only for authorised users

Schäfer A, Werner N, Westenfeld R, Moller JE, Schulze PC, Karatolios K et al (2019) Clinical scenarios for use of transvalvular microaxial pumps in acute heart failure and cardiogenic shock—a European experienced users working group opinion. Int J Cardiol 291:96–104. https://doi.org/10.1016/j.ijcard.2019.05.044CrossRefPubMed

Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D et al (2005) High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 111(7):887–893. https://doi.org/10.1161/01.CIR.0000155616.07901.35CrossRefPubMed

Escher F, Pietsch H, Aleshcheva G, Bock T, Baumeier C, Elsaesser A et al (2020) Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies. ESC Heart Fail 7(5):2440–2447. https://doi.org/10.1002/ehf2.12805CrossRefPubMedPubMedCentral

Pietsch H, Escher F, Aleshcheva G, Lassner D, Bock CT, Schultheiss HP (2020) Detection of parvovirus mRNAs as markers for viral activity in endomyocardial biopsy-based diagnosis of patients with unexplained heart failure. Sci Rep 10(1):22354. https://doi.org/10.1038/s41598-020-78597-4CrossRefPubMedPubMedCentral

Kühl U, Lassner D, Dorner A, Rohde M, Escher F, Seeberg B et al (2013) A distinct subgroup of cardiomyopathy patients characterized by transcriptionally active cardiotropic erythrovirus and altered cardiac gene expression. Basic Res Cardiol 108(5):372. https://doi.org/10.1007/s00395-013-0372-yCrossRefPubMed

Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(33):2636-48a–48d. https://doi.org/10.1093/eurheartj/eht210CrossRefPubMed

Schultheiss HP, Bock T, Pietsch H, Aleshcheva G, Baumeier C, Fruhwald F et al (2021) Nucleoside analogue reverse transcriptase inhibitors improve clinical outcome in transcriptional active human parvovirus B19-positive patients. J Clin Med. https://doi.org/10.3390/jcm10091928CrossRefPubMedPubMedCentral

Schultheiss HP, Piper C, Sowade O, Waagstein F, Kapp JF, Wegscheider K et al (2016) Betaferon in chronic viral cardiomyopathy (BICC) trial: effects of interferon-beta treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol 105(9):763–773. https://doi.org/10.1007/s00392-016-0986-9CrossRefPubMed

Van Linthout S, Elsanhoury A, Klein O, Sosnowski M, Miteva K, Lassner D et al (2018) Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity. ESC Heart Fail 5(5):818–829. https://doi.org/10.1002/ehf2.12341CrossRefPubMedPubMedCentral

10.

Wang GQ, Ding YP, Dong YH (2013) Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients. J Viral Hepat 20(Suppl 1):9–17. https://doi.org/10.1111/jvh.12059CrossRefPubMed

11.

Tschöpe C, Van Linthout S, Klein O, Mairinger T, Krackhardt F, Potapov EV et al (2019) Mechanical unloading by fulminant myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA concepts. J Cardiovasc Transl Res 12(2):116–123. https://doi.org/10.1007/s12265-018-9820-2CrossRefPubMed

Title: Fulminant parvovirus B19 myocarditis after chemotherapy: full recovery after antiviral therapy with tenofovir
Authors: Tobias Koenig
Tibor Kempf
Heinz-Peter Schultheiss
Markus Cornberg
Johann Bauersachs
Andreas Schäfer
Publication date: 01-02-2022
Publisher: Springer Berlin Heidelberg
Keywords: Fifth Disease
Myocarditis
Telbivudin
Tenofovir
Heart Failure
Cytostatic Therapy
Published in: Clinical Research in Cardiology / Issue 2/2022
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-021-01955-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Fulminant parvovirus B19 myocarditis after chemotherapy: full recovery after antiviral therapy with tenofovir

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2022

Correction to: The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome

Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry

Alcohol-induced right bundle branch block is associated with a benign outcome in HOCM after alcohol septum ablation (ASA)

Determinants of soluble angiotensin-converting enzyme 2 concentrations in adult patients with complex congenital heart disease

Correction to: Five-year results of heart rate control with ivabradine or metoprolol succinate in patients after heart transplantation

The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome